default author photo

Howard Sandler

Cedars Sinai Medical Center - Department of Radiation Oncology

8700 Beverly Blvd.

Los Angeles, CA 90048

United States

SCHOLARLY PAPERS

1

DOWNLOADS

42

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

First-in-Human Phase 1 Study of Veliparib, a PARP-1/2 Inhibitor, with Gemcitabine and Radiotherapy in Locally Advanced Pancreatic Cancer

Number of pages: 71 Posted: 21 Dec 2018
Richard Tuli, Stephen Shiao, Nicholas Nissen, Mourad Tighiouart, Sungjin Kim, Arsen Osipov, Miranda Bryant, Lindsey Ristow, Veronica Placencio, David Hoffman, Sepehr Rokhsar, Kevin Scher, Samuel Klempner, Paul Noe, MJ Davis, Ashley Wachsman, Simon Lo, Laith Jamil, Howard Sandler, Steven Piantadosi and Andrew Hendifar
Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Medicine, Cedars Sinai Medical Center - Department of Radiation Oncology, Cedars Sinai Medical Center - Department of Medicine and Cedars Sinai Medical Center - Department of Medicine
Downloads 42 (1,157,785)

Abstract:

Loading...

parp inhibitor, radiation, gemcitabine, pancreas cancer, Veliparib